Investor Presentaiton

Next Wave New project: DS-3939 starts Ph1/2 study DXD-ADC directed TA-MUC1 (DAR: 8) Ph1/2 study in solid tumors is planned to start in FY2023 Q2 Dose Escalation Part DS-3939 (IV, Q3W) Ph1/2 Study Design Locally advanced, metastatic, or unresectable NSCLC, BC, UC, Dose Expansion Part DS-3939 (IV, Q3W) Multiple expansion cohorts targeting various advanced solid tumors OVC, BTC, or PDAC Evaluate safety and preliminary efficacy ■DS-3939 is an ADC developed by Daiichi-Sankyo combining an anti-TA-MUC1 antibody in-licensed from Glycotope GmbH (Berlin, Germany) and Daiichi Sankyo's DXD-ADC technology ■Tumor-associated Mucin 1 (TA-MUC1) is a transmembrane glycoprotein overexpressed in LC, BC, OVC, and other tumor types ■FIH study in solid tumors composed of dose escalation and dose expansion part is planned to start in FY2023 Q2 BC: breast cancer, BTC: biliary tract cancer, DAR: drug-antibody ratio, IV: intravenous, LC: lung cancer, NSCLC: non-small cell lung cancer, OVC: ovarian cancer, PDAC: pancreatic ductal adenocarcinoma, Q3W: every 3 weeks, UC: urothelial cancer 26

View entire presentation